Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Liu

Showing results (201-210 of 234) with videos related to

Pageof 24
Sort By:
Journal of Virology|November 21, 2020
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoVAleksandra Milewska, Ying Chi, Artur Szczepanski, et al.
Plos Biology|January 15, 2020
Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interactionAshley L Comer, Tushare Jinadasa, Balaji Sriram, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA studyMeletios A Dimopoulos, Paul G Richardson, Rudolf Schlag, et al.
Blood|July 15, 2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneJean-Luc Harousseau, Antonio Palumbo, Paul G Richardson, et al.
Oncogene|December 19, 2018
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastomaTiantian Cui, Erica H Bell, Joseph McElroy, et al.
Probiotics and Antimicrobial Proteins|June 11, 2021
The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader-Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled TrialXue-Jun Kong, Kevin Liu, Patrick Zhuang, et al.
Biorxiv : the Preprint Server for Biology|April 28, 2025
Mitochondrial Responses to Conventional and Ultra-high Dose Rate (FLASH) RadiationEmily G Caggiano, Alan Lopez Hernandez, Trey Waldrop, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
Frontiers in Nutrition|March 8, 2021
The Effects of Probiotic Supplementation on Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi Syndrome: A Randomized Double-Blinded Placebo-Controlled TrialXue-Jun Kong, Guobin Wan, Ruiyi Tian, et al.
Pageof 24

Showing results (201-210 of 234) with videos related to

Sort By:
Pageof 24
Journal of Virology|November 21, 2020
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoVAleksandra Milewska, Ying Chi, Artur Szczepanski, et al.
Plos Biology|January 15, 2020
Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interactionAshley L Comer, Tushare Jinadasa, Balaji Sriram, et al.
Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA studyMeletios A Dimopoulos, Paul G Richardson, Rudolf Schlag, et al.
Blood|July 15, 2010
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisoneJean-Luc Harousseau, Antonio Palumbo, Paul G Richardson, et al.
Oncogene|December 19, 2018
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastomaTiantian Cui, Erica H Bell, Joseph McElroy, et al.
Probiotics and Antimicrobial Proteins|June 11, 2021
The Effects of Limosilactobacillus reuteri LR-99 Supplementation on Body Mass Index, Social Communication, Fine Motor Function, and Gut Microbiome Composition in Individuals with Prader-Willi Syndrome: a Randomized Double-Blinded Placebo-Controlled TrialXue-Jun Kong, Kevin Liu, Patrick Zhuang, et al.
Biorxiv : the Preprint Server for Biology|April 28, 2025
Mitochondrial Responses to Conventional and Ultra-high Dose Rate (FLASH) RadiationEmily G Caggiano, Alan Lopez Hernandez, Trey Waldrop, et al.
British Journal of Haematology|March 8, 2011
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trialPaul Richardson, Rudolf Schlag, Nuriet Khuageva, et al.
Frontiers in Nutrition|March 8, 2021
The Effects of Probiotic Supplementation on Anthropometric Growth and Gut Microbiota Composition in Patients With Prader-Willi Syndrome: A Randomized Double-Blinded Placebo-Controlled TrialXue-Jun Kong, Guobin Wan, Ruiyi Tian, et al.
Pageof 24